Stray Dog

Hims & Hers adds Eli Lilly's Zepbound and Foundayo

  • Good news: Hims now offers Lilly's Zepbound from $299 a month and oral Foundayo from $149 a month, alongside its Novo Nordisk partnership.
  • Mixed: Hims pledges never to sell compounded Lilly drugs, easing its reliance on compounding, though its own compounded semaglutide continues.
  • Bad news: Hims gets no markup on the drugs, and Q2 gross margin has already fallen from 76% to 64%.
Read the full notes

Eli Lilly has formally partnered with Hims & Hers (joint press release, 6 Nov). Eligible patients can get Zepbound injectable (tirzepatide) and Foundayo oral (orforglipron) through Hims, with consultation, prescription and delivery all on the platform. Cash prices match Lilly's direct-to-consumer prices:

Read more

Foundayo from $149 a month and Zepbound from $299 a month. Together with the resumed Novo Nordisk partnership (Mar 2026), Hims now has legitimate channel access to both leading branded GLP-1s. That structurally reduces its dependence on compounded versions and its exposure to a rollback of compounding policy. There are two explicit commitments: (1) Hims has never sold a compounded version of a Lilly drug and will not; (2) the platform's physicians keep their prescribing independence, which directly addresses the 2025 split with Novo. Foundayo at $149 a month is the lowest entry point among branded weight-loss drugs, and a new way to attract users who dislike injections or are price sensitive. The margin concern remains. Hims gets no pricing advantage and no markup, so revenue comes only from membership and cross-selling. Q2 gross margin has already fallen from 76% to 64%, and the branded drug ramp keeps pressing on margins. No financial terms were disclosed and there is no 8-K on EDGAR, so the company does not treat this as a material contract. The scope is limited: the no-compounding commitment applies to Lilly only and does not affect Hims' own compounded semaglutide business. The key checks come at Q3 earnings after the market closes on 9 Nov: the branded weight-loss mix, dilution of monthly revenue per user, gross margin holding near 64%, and management's comments on the pace and economics of the Lilly channel ramp.

Key evidence

  • Joint press release, 6 Nov: eligible patients on the Hims platform can access Lilly's injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron)
  • Cash prices: Foundayo from $149 a month and Zepbound from $299 a month, the same as any Lilly direct-to-consumer cash patient pays
  • Fierce Healthcare: Lilly lets the Hims pharmacy source directly at the cash price
  • Commitment 1: Hims has never sold a compounded version of a Lilly drug and will not in future
  • Commitment 2: both parties pledge to protect the independent prescribing judgement of the platform's physicians
  • This directly addresses the 2025 split with Novo Nordisk, which accused Hims of steering patients to compounded versions
Show 6 more
  • With the Novo partnership resumed in Mar 2026, Hims has both major branded weight-loss channels
  • Foundayo at $149 a month is the lowest entry point among branded weight-loss drugs, and appeals to users who dislike injections or are price sensitive
  • No pricing advantage and no markup for Hims: revenue comes only from membership fees and cross-selling
  • Q2 gross margin has already fallen from 76% to 64% because of the branded drug ramp
  • No financial terms disclosed and no 8-K on EDGAR, so this is not treated as a material contract
  • The compounding commitment applies to Lilly only and does not affect Hims' own compounded semaglutide business

Catalysts to watch

  • Q3 earnings after the market closes on 9 Nov: the main test
  • Disclosure of the branded weight-loss drug mix
  • Dilution of monthly revenue per user
  • Gross margin holding at about 64%
  • Management's comments on the pace and economics of the Lilly channel ramp
  • Uptake of oral Foundayo as an entry point

Risks

  • The branded drug ramp keeps pressing gross margin below 64%
  • The platform has limited pricing power against pharma: it captures revenue only from membership and cross-selling
  • The risk of a rollback of compounding policy is reduced but not removed (Hims' own compounded semaglutide continues)
  • The lack of any material contract disclosure suggests limited near-term financial impact
  • Revenue per user is diluted if entry-level Foundayo cannibalises higher-priced subscriptions
  • Execution risk on the pace of the Lilly channel ramp

Sources 5

  1. news.hims.com (press release, 6 Nov)
  2. investors.hims.com
  3. Business Wire original press release
  4. Fierce Healthcare (Lilly cash price sourcing)
  5. SEC EDGAR (no 8-K confirmation)